From December 2023 to May 2024, we conducted a clinical trial of CD19/CD22 dual-target CAR-T-cell therapy to evaluate its efficacy and safety in patients with r/r DLBCL. This evidence concerns the gene CD22 and diffuse large B-cell lymphoma.